Puma Biotechnology
PBYI
125 hedge funds and large institutions have $309M invested in Puma Biotechnology in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 24 closing their positions.
12.74% more ownership
Funds ownership: 80.46% → 93.2% (+13%)
13% more capital invested
Capital invested by funds: $274M → $309M (+$34.7M)
2% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 43
9% less call options, than puts
Call options by funds: $3.45M | Put options by funds: $3.81M
6% less funds holding
Funds holding: 133 → 125 (-8)
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$24.6M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$18.9M |
| 3 |
Renaissance Technologies
New York
|
+$9.63M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.3M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$6.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$7.78M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.9M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.49M |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$2.05M |
PBYI Hedge Fund Activity: Q1 2020 in Review
125 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2020, worth a combined $309M — up 13% from $274M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of PBYI and 19 opened new positions — a net loss of 5 holders — while 43 trimmed existing stakes and 42 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $24.6M. The largest seller was Nuveen, cutting an estimated $7.78M.
- 125 institutional investors held Puma Biotechnology (PBYI) as of Q1 2020, down from 133 in Q4 2019.
- Funds reported $309M of Puma Biotechnology stock for Q1 2020, up 13% quarter-over-quarter.
- 19 funds opened new Puma Biotechnology positions in Q1 2020 and 24 closed out, a net change of -5 holders.
- The largest Puma Biotechnology buyer in Q1 2020 was EcoR1 Capital, an estimated $24.6M added.
- The largest Puma Biotechnology seller in Q1 2020 was Nuveen, an estimated $7.78M sold.
Based on aggregated 13F filings for Q1 2020.